Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CBMX reversing +11%
We need to implement some runners' rules, too many at a time no bueno :)
Definitely on watch for that 200MA break.
One straight arrow up, wow.
Yeah, actually too many. Missing my entry points here, sheesh.
SWSH: +20%
Past the 100MA.
PPHM +16%
Yeah, the surge over $2 was inviting.
Looks like 1.5M volume not that far off, selling back/forth?
Desperately tried to hold 3.80 but we've just broken through.
THQI moving
My brother did tell me they had another promo running. Don't like the big sell block, now though.
Nice, break .92 and we're off.
CLSN: +5% on gap up
That's one way of breaking new highs.
Admit it, $F, that 40K spike is all you LOL
Someone wants in, worth watching.
MCP back at break-even
What a yoyo today. People still digesting the CEO departure.
Looks like we posted simultaneously. :)
Solars on fire. Thx for STP
TSL JASO FSLR JKS LDK
Hard to find a solar not running. Seen the news about China pumping more billions in the solar industry?
They do say some pumps reach for the sky :)
holding up remarkably well right now, perhaps another test of 2.48 coming.
You'd think they'd found a way to get humans to Mars ;)
TEK: +19%
At it again.
ABIO gapped up on news
ARCA biopharma, Inc. (Nasdaq: ABIO) announces the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation" was published
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation" was published in the European Journal of Heart Failure (www.escardio.org/journals/european-journal-heart-failure), a publication of the Heart Failure Association of the European Society of Cardiology.
The paper discusses post-hoc analyses of data from the Phase 3 clinical study of Gencaro in heart failure, known as the Beta-Blocker Evaluation of Survival Trial (BEST), which was sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs. These data demonstrate that patients with established atrial fibrillation (AF) in BEST who received Gencaro had improvements in heart failure clinical endpoints. Compared to placebo, the effects of Gencaro on improving heart failure clinical endpoints in the 303 patients in BEST with established AF were generally similar to the effects of Gencaro on these endpoints in the 2,176 patients in BEST with normal sinus rhythm.
Ziopharm Oncology Cut to Hold From Buy by Jefferies
-4% PM
Sucampo's Supplemental NDA For Intraocular Pressure Treatment Gets FDA Approval
Sucampo Pharmaceuticals Inc.'s (SCMP) supplemental new drug application for its treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension has received approval from the U.S. Food and Drug Administration.
The approval is for Sucampo's Rescula solution, which the drug company intends to commercialize in the first quarter of next year.
According to the approved product labeling, Rescula may be used as a first-line agent or along with other topical ophthalmic drug products to lower intraocular pressure.
"Rescula provides IOP [intraocular pressure] reduction by increasing trabecular flow, and may be an appropriate choice for eye specialists who are trying to balance efficacy with management of side effects," Chief Executive Ryuji Ueno said. "It has been shown to be an effective medicine in lowering IOP in patients with open-angle glaucoma and ocular hypertension while demonstrating an excellent systemic safety profile and an established ocular side effects profile."
As per $F's post, IPO delayed.
Can't be easy for you to trade with the time difference.
Nokia shares should be avoided, says Pacific Crest
Back & forth on Nokia's sales:
After conducting checks, Pacific Crest believes that sales of Nokia's Lumia 820 and Lumia 920 are modest. The firm maintains a Sector Perform rating on the stock.
Yeah, EOD and AH action was decent. Watching for support/resistance points:
100MA support, 3.84 1st PM top, 3.92 resistance, 4.04 & 200MA?
Nice morning gains.
Did see it spike yesterday towards EOD after being pretty much dead throughout the day, but can't post them all :)
No clue about the company, though. What's the cause of the run?
Love Korean movies & women :)
Pretty clear chart, 20MA being support, 50MA being resistance. Did bounce nicely and closed above yesterday's high, and so we try again :)
ONTY slightly up in AH
Topped @ 200MA, could be more fun tomorrow.